|
Association of PIK3CA mutation with response (ExRx) to cetuximab (C) in metastatic (met) triple-negative breast cancer (TNBC). |
|
|
Consulting or Advisory Role - Theranostics Health |
|
|
No Relationships to Disclose |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Theranostics Health |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |